Nivolumab plus ipilimumab and cobimetinib in previously treated microsatellite-stable/DNA mismatch repair-proficient metastatic colorectal cancer: the phase II CheckMate 142 trial. [PDF]
Overman MJ +6 more
europepmc +1 more source
Persistent loss of animal diversity on a rocky shore over nine decades and across multiple investigators. [PDF]
Elahi R, Micheli F, Watanabe JM.
europepmc +1 more source
Dysphagia Evaluation after Stroke through Intervention with oral neuromuscular training for REhabilitation of swallowing dysfunction (DESIRE): study protocol for a multicenter randomized controlled trial. [PDF]
Hägglund P +9 more
europepmc +1 more source
Asciminib Provides Better Efficacy and Favorable Safety and Tolerability Against Investigator-Selected Tyrosine Kinase Inhibitors in East Asian Patients With Newly Diagnosed Chronic Myeloid Leukemia: Results From a Subgroup Analysis of the Pivotal ASC4FIRST Study. [PDF]
Takahashi N +20 more
europepmc +1 more source
TROPION-Urothelial03: a phase II/III study of datopotamab deruxtecan (Dato-DXd) for locally advanced or metastatic urothelial carcinoma. [PDF]
Galsky MD +17 more
europepmc +1 more source
Performance of Local Large Language Models for Adjudicating Heart Failure Hospitalizations. [PDF]
Aggarwal R +8 more
europepmc +1 more source
Endotracheal Tube Repositioning Frequency for Preventing Oral Mucosal Pressure Injuries in Intensive Care Units: A Randomised Controlled Trial Study Protocol. [PDF]
Ozdemır E, Korkmaz F, Derelı N.
europepmc +1 more source
The ARTIST Post-Market Study: Evaluating a High G' Hyaluronic Acid (HA) Injectable for Chin Combined With Midface HA Filler Treatments. [PDF]
Nikolis A +5 more
europepmc +1 more source
A one-year exploratory randomized, controlled, multicentric pilot study evaluating the efficacy and tolerance of an anti-hair loss serum containing <i>Silybum marianum</i> extract, manganese PCA, and <i>Lespedeza capitata</i> extract following hair transplantation in men with androgenic alopecia. [PDF]
Ortega Quijano D +6 more
europepmc +1 more source

